Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. (Q40274520)

From Wikidata

Jump to navigation Jump to search

scientific article published on May 2006

Language	Label	Description	Also known as
English	Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.	scientific article published on May 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

ovarian carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

Paul Workman

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

author name string

Nivedita Sain

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Bhavani Krishnan

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Michael G Ormerod

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Assunta De Rienzo

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Wai M Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Stanley B Kaye

6

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Ann L Jackman

8

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

publication date

1 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1197-1208

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

The Hallmarks of Cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Translating basic cancer research into new cancer therapeutics

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

EGFR gene mutations: a call for global x global views of cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Ovarian cancer: strategies for overcoming resistance to chemotherapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Putting the rap on Akt.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

STI571 (Gleevec) as a paradigm for cancer therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Hsp90 as a therapeutic target in prostate cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Who will benefit from treatment against EGFR?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

PIK3CA is implicated as an oncogene in ovarian cancer.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-05-0445

Identifiers

10.1158/1535-7163.MCT-05-0445

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40274520&oldid=2041991152"